Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Infarction | 21 | 2022 | 861 | 4.860 |
Why?
|
Multiple Chronic Conditions | 6 | 2023 | 37 | 3.800 |
Why?
|
Heart Failure | 12 | 2023 | 853 | 3.060 |
Why?
|
Patient Readmission | 7 | 2021 | 421 | 1.610 |
Why?
|
Multimorbidity | 7 | 2025 | 43 | 1.510 |
Why?
|
Acute Coronary Syndrome | 4 | 2017 | 250 | 1.440 |
Why?
|
Hospitalization | 13 | 2022 | 1290 | 1.440 |
Why?
|
Atrial Fibrillation | 9 | 2022 | 805 | 1.420 |
Why?
|
Chronic Disease | 6 | 2025 | 717 | 1.220 |
Why?
|
Aged | 34 | 2025 | 13406 | 1.030 |
Why?
|
Inpatients | 3 | 2019 | 292 | 1.010 |
Why?
|
Survivors | 2 | 2017 | 150 | 1.000 |
Why?
|
Diabetes Mellitus | 3 | 2022 | 515 | 0.950 |
Why?
|
Angiotensin Receptor Antagonists | 4 | 2022 | 64 | 0.880 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2022 | 142 | 0.860 |
Why?
|
Hospital Mortality | 8 | 2018 | 842 | 0.820 |
Why?
|
Hyperkalemia | 1 | 2022 | 19 | 0.800 |
Why?
|
Male | 39 | 2025 | 27747 | 0.800 |
Why?
|
Massachusetts | 16 | 2021 | 2019 | 0.780 |
Why?
|
Retrospective Studies | 15 | 2023 | 6071 | 0.770 |
Why?
|
Aged, 80 and over | 16 | 2023 | 5119 | 0.770 |
Why?
|
Percutaneous Coronary Intervention | 4 | 2022 | 160 | 0.760 |
Why?
|
Age Factors | 9 | 2021 | 1504 | 0.750 |
Why?
|
Electrocardiography | 2 | 2015 | 521 | 0.740 |
Why?
|
Female | 38 | 2025 | 30724 | 0.700 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 132 | 0.700 |
Why?
|
Risk Factors | 15 | 2022 | 4986 | 0.690 |
Why?
|
Mobility Limitation | 1 | 2020 | 47 | 0.690 |
Why?
|
Morbidity | 1 | 2020 | 113 | 0.680 |
Why?
|
Chest Pain | 2 | 2020 | 81 | 0.660 |
Why?
|
Humans | 44 | 2025 | 59389 | 0.620 |
Why?
|
Independent Living | 1 | 2018 | 44 | 0.590 |
Why?
|
Risk Assessment | 7 | 2022 | 1925 | 0.590 |
Why?
|
Anemia | 1 | 2019 | 119 | 0.590 |
Why?
|
Disease Management | 1 | 2019 | 220 | 0.570 |
Why?
|
Middle Aged | 20 | 2025 | 16314 | 0.560 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2017 | 147 | 0.550 |
Why?
|
Length of Stay | 7 | 2017 | 776 | 0.540 |
Why?
|
Time Factors | 10 | 2019 | 3615 | 0.520 |
Why?
|
Psychosocial Deprivation | 1 | 2015 | 8 | 0.510 |
Why?
|
Research | 1 | 2017 | 188 | 0.500 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 454 | 0.490 |
Why?
|
Survival Rate | 5 | 2019 | 801 | 0.470 |
Why?
|
Cardiac Catheterization | 2 | 2022 | 253 | 0.470 |
Why?
|
Patient Discharge | 6 | 2017 | 492 | 0.450 |
Why?
|
Follow-Up Studies | 6 | 2019 | 2338 | 0.450 |
Why?
|
Quality of Life | 6 | 2022 | 1137 | 0.440 |
Why?
|
Myocardial Revascularization | 1 | 2014 | 71 | 0.430 |
Why?
|
Diabetes Complications | 1 | 2014 | 100 | 0.430 |
Why?
|
Secondary Prevention | 1 | 2014 | 151 | 0.420 |
Why?
|
Delivery of Health Care | 1 | 2017 | 413 | 0.420 |
Why?
|
Forecasting | 1 | 2014 | 221 | 0.410 |
Why?
|
Primary Prevention | 1 | 2014 | 134 | 0.400 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 211 | 0.390 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 204 | 0.390 |
Why?
|
Comorbidity | 6 | 2020 | 1078 | 0.360 |
Why?
|
Multivariate Analysis | 4 | 2017 | 902 | 0.360 |
Why?
|
Sex Factors | 6 | 2020 | 935 | 0.360 |
Why?
|
Anxiety | 2 | 2020 | 387 | 0.340 |
Why?
|
Treatment Outcome | 8 | 2017 | 5281 | 0.320 |
Why?
|
Frailty | 2 | 2022 | 124 | 0.310 |
Why?
|
Anxiety Disorders | 1 | 2011 | 186 | 0.310 |
Why?
|
Caregivers | 2 | 2025 | 231 | 0.310 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 789 | 0.310 |
Why?
|
Chi-Square Distribution | 4 | 2017 | 409 | 0.300 |
Why?
|
Stroke | 4 | 2022 | 1127 | 0.300 |
Why?
|
Depressive Disorder, Major | 1 | 2011 | 246 | 0.290 |
Why?
|
Cause of Death | 2 | 2019 | 210 | 0.290 |
Why?
|
United States | 5 | 2025 | 7426 | 0.280 |
Why?
|
Depression | 2 | 2020 | 829 | 0.260 |
Why?
|
Coronary Artery Bypass | 3 | 2022 | 275 | 0.250 |
Why?
|
Prognosis | 5 | 2017 | 1597 | 0.240 |
Why?
|
Cohort Studies | 5 | 2018 | 2375 | 0.220 |
Why?
|
Prevalence | 2 | 2019 | 1253 | 0.220 |
Why?
|
Potassium | 1 | 2022 | 100 | 0.200 |
Why?
|
Medical Records, Problem-Oriented | 1 | 2021 | 13 | 0.180 |
Why?
|
Adult | 7 | 2025 | 15683 | 0.180 |
Why?
|
Parents | 1 | 2025 | 367 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 266 | 0.180 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2022 | 54 | 0.180 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 263 | 0.180 |
Why?
|
Anticoagulants | 2 | 2022 | 480 | 0.180 |
Why?
|
Needs Assessment | 1 | 2021 | 187 | 0.170 |
Why?
|
Frail Elderly | 1 | 2020 | 107 | 0.160 |
Why?
|
Hemorrhage | 1 | 2021 | 260 | 0.160 |
Why?
|
Antiviral Agents | 1 | 2022 | 313 | 0.160 |
Why?
|
Adaptation, Psychological | 2 | 2012 | 259 | 0.160 |
Why?
|
Musculoskeletal Diseases | 1 | 2020 | 101 | 0.160 |
Why?
|
Osteoarthritis | 1 | 2020 | 131 | 0.150 |
Why?
|
Prospective Studies | 4 | 2022 | 3067 | 0.150 |
Why?
|
Incidence | 3 | 2018 | 1238 | 0.140 |
Why?
|
Logistic Models | 3 | 2016 | 1234 | 0.140 |
Why?
|
Disease-Free Survival | 1 | 2017 | 228 | 0.140 |
Why?
|
Drug Interactions | 1 | 2017 | 115 | 0.140 |
Why?
|
Surveys and Questionnaires | 3 | 2022 | 2516 | 0.130 |
Why?
|
Patient Care Management | 1 | 2016 | 30 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 114 | 0.130 |
Why?
|
Lung Diseases | 1 | 2017 | 170 | 0.130 |
Why?
|
Patient Outcome Assessment | 1 | 2016 | 52 | 0.130 |
Why?
|
Health Services Research | 1 | 2017 | 266 | 0.130 |
Why?
|
Georgia | 1 | 2015 | 87 | 0.120 |
Why?
|
Hypolipidemic Agents | 1 | 2015 | 25 | 0.120 |
Why?
|
Diuretics | 1 | 2015 | 59 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 2015 | 56 | 0.120 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 130 | 0.120 |
Why?
|
Electronic Health Records | 1 | 2018 | 342 | 0.120 |
Why?
|
Self Report | 3 | 2022 | 359 | 0.120 |
Why?
|
Health Status | 1 | 2017 | 426 | 0.120 |
Why?
|
Aging | 1 | 2020 | 710 | 0.110 |
Why?
|
Stroke Volume | 1 | 2015 | 314 | 0.110 |
Why?
|
Longitudinal Studies | 1 | 2017 | 1189 | 0.110 |
Why?
|
Personality Inventory | 2 | 2011 | 54 | 0.100 |
Why?
|
Academic Medical Centers | 1 | 2015 | 308 | 0.100 |
Why?
|
Aspirin | 1 | 2014 | 167 | 0.100 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 1027 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2013 | 210 | 0.090 |
Why?
|
Models, Psychological | 1 | 2012 | 94 | 0.090 |
Why?
|
Cross-Sectional Studies | 2 | 2025 | 2380 | 0.090 |
Why?
|
Case-Control Studies | 1 | 2014 | 1051 | 0.090 |
Why?
|
Angina, Unstable | 1 | 2011 | 57 | 0.090 |
Why?
|
Pediatrics | 1 | 2013 | 241 | 0.090 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 379 | 0.090 |
Why?
|
Fear | 1 | 2011 | 65 | 0.090 |
Why?
|
Body Mass Index | 1 | 2014 | 831 | 0.080 |
Why?
|
Mental Health Services | 1 | 2013 | 269 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2015 | 1479 | 0.080 |
Why?
|
Health Services Accessibility | 1 | 2013 | 527 | 0.080 |
Why?
|
Sex Distribution | 2 | 2018 | 244 | 0.070 |
Why?
|
Age Distribution | 2 | 2018 | 249 | 0.070 |
Why?
|
Geriatric Assessment | 2 | 2020 | 159 | 0.070 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2024 | 43 | 0.060 |
Why?
|
Health Surveys | 1 | 2025 | 298 | 0.050 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2002 | 10 | 0.050 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2002 | 19 | 0.050 |
Why?
|
Fluoxetine | 1 | 2002 | 44 | 0.050 |
Why?
|
Odds Ratio | 2 | 2015 | 746 | 0.050 |
Why?
|
Acute Disease | 2 | 2015 | 658 | 0.050 |
Why?
|
Perception | 1 | 2022 | 168 | 0.050 |
Why?
|
Antidepressive Agents | 1 | 2002 | 212 | 0.050 |
Why?
|
Patient Reported Outcome Measures | 1 | 2021 | 126 | 0.040 |
Why?
|
Depressive Disorder | 1 | 2002 | 279 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2020 | 289 | 0.040 |
Why?
|
Cognition | 1 | 2022 | 454 | 0.040 |
Why?
|
Social Support | 1 | 2020 | 355 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2020 | 246 | 0.040 |
Why?
|
Urban Health | 1 | 2015 | 40 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2015 | 50 | 0.030 |
Why?
|
Exercise | 1 | 2022 | 883 | 0.030 |
Why?
|
Young Adult | 1 | 2025 | 4272 | 0.030 |
Why?
|
Shock, Cardiogenic | 1 | 2015 | 85 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 241 | 0.030 |
Why?
|
Checklist | 1 | 2013 | 72 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2013 | 589 | 0.020 |
Why?
|
Survival Analysis | 1 | 2013 | 554 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 674 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2013 | 292 | 0.020 |
Why?
|
Edema | 1 | 2010 | 42 | 0.020 |
Why?
|
Dyspnea | 1 | 2010 | 116 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2010 | 278 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 705 | 0.020 |
Why?
|
Adolescent | 2 | 2013 | 5838 | 0.020 |
Why?
|
Cough | 1 | 2010 | 183 | 0.020 |
Why?
|
Mass Screening | 1 | 2013 | 648 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2010 | 692 | 0.010 |
Why?
|
Child | 1 | 2013 | 4189 | 0.010 |
Why?
|
Postmenopause | 1 | 2002 | 224 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2002 | 805 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2002 | 715 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2002 | 678 | 0.010 |
Why?
|